Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.
Barcelona, Spain. In Oncotarget, 10 Apr 2014
In this respect, rucaparib inhibits nine kinases with micromolar affinity, including PIM1, PIM2, PRKD2, DYRK1A, CDK1, CDK9, HIPK2, CK2, and ALK.
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Ann Arbor, United States. In Diabetes Care, Aug 2013
Recent phase I and phase II clinical trials in humans have shown that the GPR40 agonist TAK-875 reduces fasting and postprandial blood glucose and lowers HbA1c with efficacy equal to that of the sulfonylurea glimepiride without inducing hypoglycemia or evidence of tachyphylaxis.
Efficacy and toxicity of factor Xa inhibitors.
Marseille, France. In J Pharm Pharm Sci, 2012
New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations.